Patents Assigned to ETHERNA IMMUNOTHERAPIES NV
-
Publication number: 20240050574Abstract: The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.Type: ApplicationFiled: December 23, 2021Publication date: February 15, 2024Applicants: eTheRNA immunotherapies NV, Universiteit GentInventors: Stefaan DE KOKER, Bruno DE GEEST, Chen YONG
-
Publication number: 20240016738Abstract: The present invention relates to the field of lipid nanoparticles (LNP); more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response. The present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.Type: ApplicationFiled: May 11, 2023Publication date: January 18, 2024Applicants: ETHERNA IMMUNOTHERAPIES NV, Vrije Universiteit BrusselInventors: Stefaan DE KOKER, Sanne BEVERS, Peter TOMME
-
Patent number: 11684577Abstract: The present invention relates to the field of lipid nanoparticles (LPN); more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response. The present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.Type: GrantFiled: January 18, 2019Date of Patent: June 27, 2023Assignees: ETHERNA IMMUNOTHERAPIES NV, Vrije Unversiteit BrusselInventors: Stefaan De Koker, Sanne Bevers, Peter Tomme
-
Publication number: 20220387573Abstract: The present invention in general relates to combinations of mRNA molecules encoding CD40, caTLR4 and CD70 with mRNA molecules encoding tumor-associated antigens for use as therapeutic vaccine in the treatment of metastatic cancer patients primarily with stable malignant melanoma disease, but also extending into other cancer types and to patient whose disease has shown partial response on prior therapy. Said uses may further encompass the administration of checkpoint inhibitors. The present invention further provides administration schemes for such therapies focusing on administration of the therapeutic into lymph nodes, so called intra-nodal therapy.Type: ApplicationFiled: June 29, 2020Publication date: December 8, 2022Applicant: eTheRNA immunotherapies NVInventors: Marina Cools, Tim Van Assche, Brenda De Keersmaecker
-
Publication number: 20200345641Abstract: The present invention relates to the field of lipid nanoparticles more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response. The present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.Type: ApplicationFiled: January 18, 2019Publication date: November 5, 2020Applicant: ETHERNA IMMUNOTHERAPIES NVInventors: Stefaan DE KOKER, Sanne BEVERS, Peter TOMME